Literature DB >> 3115843

Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1.

I Juhan-Vague1, P Vague, M C Alessi, C Badier, J Valadier, M F Aillaud, C Atlan.   

Abstract

Low fibrinolytic activity, as measured by euglobulin (EFA), has been observed in obese subjects, and hypofibrinolysis may play a role in the pathogenesis of atherosclerosis and its complications. Blood fibrinolytic activity is regulated through a complex system of activators and inhibitors, especially plasminogen activator inhibitors (PA Inhibitors). In a group of 35 non-diabetic subjects with a wide range of body mass index (BMI), EFA was negatively correlated, and PA Inhibitor activity positively correlated, with BMI and plasma insulin levels. In a population of 49 non-diabetic obese women (differing from a control group of normal weight by lower EFA and higher level, of PA Inhibitor activity, plasma insulin and triglyceride), the PA Inhibitor activity was positively correlated with BMI, insulin and triglyceride. The increase in PA Inhibitor activity was associated with a high value of PA Inhibitor 1 antigen measured by an immuno-radiometric assay, indicating that the increased activity was due to a high level of circulating PA Inhibitor 1. Plasma insulin was lowered in obese non-diabetic subjects, without modification of the body weight, by a 24 hour fast or by treatment with Metformin. After 24 hours' fast, ten obese subjects had lower levels of insulin and PA Inhibitor activity and an increase in EFA. Treatment for 15 days by 1.75 g Metformin (or placebo), on a weight maintaining diet, induced, in the Metformin group, a decrease in plasma insulin, triglyceride and PA Inhibitor activity and an increase in EFA, while no change was observed in the placebo group.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3115843

Source DB:  PubMed          Journal:  Diabete Metab        ISSN: 0338-1684


  24 in total

Review 1.  Coronary heart disease in diabetes mellitus--antecedents and associations.

Authors:  P H Winocour
Journal:  Postgrad Med J       Date:  1991-10       Impact factor: 2.401

2.  Interaction of non-esterified fatty acid and insulin in control of triacylglycerol secretion by Hep G2 cells.

Authors:  C D Byrne; N P Brindle; T W Wang; C N Hales
Journal:  Biochem J       Date:  1991-11-15       Impact factor: 3.857

Review 3.  Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.

Authors:  Matteo Cesari; Marco Pahor; Raffaele Antonelli Incalzi
Journal:  Cardiovasc Ther       Date:  2010-07-07       Impact factor: 3.023

Review 4.  Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease.

Authors:  Victoria A Ploplis
Journal:  Curr Drug Targets       Date:  2011-11       Impact factor: 3.465

Review 5.  Triglycerides and disease.

Authors:  C A Seymour; C D Byrne
Journal:  Postgrad Med J       Date:  1993-09       Impact factor: 2.401

6.  The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects.

Authors:  D K Nagi; T J Hendra; A J Ryle; T M Cooper; R C Temple; P M Clark; A E Schneider; C N Hales; J S Yudkin
Journal:  Diabetologia       Date:  1990-09       Impact factor: 10.122

Review 7.  Environmental and Genetic Risk Factors Associated with Venous Thromboembolism.

Authors:  Marta Crous-Bou; Laura B Harrington; Christopher Kabrhel
Journal:  Semin Thromb Hemost       Date:  2016-10-20       Impact factor: 4.180

8.  Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men.

Authors:  A Asplund-Carlson; A Hamsten; B Wiman; L A Carlson
Journal:  Diabetologia       Date:  1993-09       Impact factor: 10.122

9.  In young post-myocardial infarction male patients elevated plasminogen activator inhibitor-1 correlates with insulin resistance and endothelial dysfunction.

Authors:  Barbara Eržen; Mišo Šabovič
Journal:  Heart Vessels       Date:  2012-09-22       Impact factor: 2.037

10.  Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta.

Authors:  M S Sawdey; D J Loskutoff
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.